|Early Drug Development in cooperation with the Pharmaceutical Industry|
Epitome Pharmaceuticals identifies, develops and licenses promising medications and technologies. Investigation is conducted by reading the scientific literature, discussing anomalies and questions with leaders in their fields, and by statistical reanalysis of published data.
Once a remedy has been identified and intellectual property rights secured, we proceed to advance the development of the medication. We clarify regulatory issues through close cooperation with regulatory agencies. Based on our research and the prospects for a specific medication, we may file an IND and initiate Phase I or Phase II trials.
Ultimately, Epitome Pharmaceuticals seeks to license its intellectual property to a partner (or partners) with the resources and capabilities to complete clinical trials, secure regulatory approval and bring a product to market most effectively.
April 2014 –
Twin Sample™ Biopsy Needle featured at Epitome Pharmaceuticals (Booth 447) AACR Annual Meeting 2014 April 5-9, San Diego Convention Center, San Diego, CA
Epitome presents research on Warfarin dosing and INR variability at Thrombosis and Hemostasis Summit of North America (THSNA) April 10-12, 2014, Sheraton Hotel & Towers, Chicago, IL
December 2013 – Twin Sample™ Biopsy Needle featured at the Gallini Booth (3111) at Radiological Society of North America Assembly and Annual Meeting. December 1-6, McCormick Place, Chicago, IL
October 2013 – Epitome introduces the Twin Sample™ Biopsy Needle at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. October 19-23, Hynes Convention Center, Boston, MA
October 2011 – US Patent Office grants patent for Epitome Pharmaceuticals' Lip balm formulation for cold sore prevention.
October 2006 – US FDA approves Veregen®, the first botanical approved under new regulations.
Twin Sample™ is a trademark of Epitome Pharmaceuticals Limited.
Veregen® is a registered trademark of MediGene AG.